The antiserum was produced against synthesized peptide derived from human IKK-alpha/beta around the phosphorylation site of Ser180/181. AA range:151-200

This antibody detects endogenous levels of IKKα/β only when phosphorylated at Human:S180/S181, Mouse:S180/S181, Rat:S180/S181..The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):CTsFV

CHUK/IKBKB

Inhibitor of nuclear factor kappa-B kinase subunit alpha

CHUK ;
IKKA ;
TCF16 ;
Inhibitor of nuclear factor kappa-B kinase subunit alpha ;
I-kappa-B kinase alpha ;
IKK-A ;
IKK-alpha ;
IkBKA ;
IkappaB kinase ;
Conserved helix-loop-helix ubiquitous kinase ;
I-kappa-B kinase 1 ;
IKK1 ;
Nuclear factor NF-kappa-B

This gene encodes a member of the serine/threonine protein kinase family. The encoded protein , a component of a cytokine-activated protein complex that is an inhibitor of the essential transcription factor NF-kappa-B complex , phosphorylates sites that trigger the degradation of the inhibitor via the ubiquination pathway , thereby activating the transcription factor. [provided by RefSeq , Jul 2008] ,

Catalytic activity:ATP + [I-kappa-B protein] = ADP + [I-kappa-B phosphoprotein]. ,enzyme regulation:Activated when phosphorylated and inactivated when dephosphorylated. ,Function:Acts as part of the IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. As part of the non-canonical pathway of NF-kappa-B activation , the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB , inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. Also phosphorylates NCOA3. Phosphorylates 'Ser-10' of histone H3 at NF-kappa-B-regulated promoters during inflammatory responses triggered by cytokines. ,PTM:Phosphorylated by MAP3K14/NIK , AKT and to a lesser extent by MEKK1 , and dephosphorylated by PP2A. Autophosphorylated. ,similarity:Belongs to the protein kinase superfamily. ,similarity:Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily. ,similarity:Contains 1 protein kinase domain. ,subcellular location:Shuttles between the cytoplasm and the nucleus. ,subunit:Component of the I-kappa-B-kinase (IKK) core complex consisting of CHUK , IKBKB and IKBKG; probably four alpha/CHUK-beta/IKBKB dimers are associated with four gamma/IKBKG subunits. The IKK core complex seems to associate with regulatory or adapter proteins to form a IKK-signalosome holo-complex. Part of a complex composed of NCOA2 , NCOA3 , CHUK/IKKA , IKBKB , IKBKG and CREBBP. Part of a 70-90 kDa complex at least consisting of CHUK/IKKA , IKBKB , NFKBIA , RELA , IKBKAP and MAP3K14. Directly interacts with IKK-gamma/NEMO and TRPC4AP (By similarity) . May interact with TRAF2. Interacts with NALP2. May interact with MAVS/IPS1. ,tissue specificity:Widely expressed. ,

Cytoplasm . Nucleus . Shuttles between the cytoplasm and the nucleus.

>>Antifolate resistance ;
>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Chemokine signaling pathway ;
>>NF-kappa B signaling pathway ;
>>FoxO signaling pathway ;
>>mTOR signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Apoptosis ;
>>Osteoclast differentiation ;
>>Toll-like receptor signaling pathway ;
>>NOD-like receptor signaling pathway ;
>>RIG-I-like receptor signaling pathway ;
>>Cytosolic DNA-sensing pathway ;
>>C-type lectin receptor signaling pathway ;
>>IL-17 signaling pathway ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>TNF signaling pathway ;
>>Adipocytokine signaling pathway ;
>>Alcoholic liver disease ;
>>Alzheimer disease ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Pathogenic Escherichia coli infection ;
>>Shigellosis ;
>>Salmonella infection ;
>>Yersinia infection ;
>>Chagas disease ;
>>Toxoplasmosis ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Pancreatic cancer ;
>>Prostate cancer ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Small cell lung cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis